Low CSF concentration of a dopamine metabolite in tobacco smokers

American Journal of Psychiatry

Volumn 156, Issue 1, 1999, Pages 130-132

  Geracioti Jr , Thomas D ^a   West, Scott A ^b   Baker, Dewleen G ^b   Hill, Kelly K ^b   Ekhator, Nosa N ^b   Wortman, Matthew D ^b   Keck Jr , Paul E ^b   Norman, Andrew B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; HOMOVANILLIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOPAMINE METABOLISM; HUMAN; PRIORITY JOURNAL; SMOKING;

EID: 0344197609     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.1.130     Document Type: Article

References (18)

1. Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M: Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:294-305
2. DiChiara G, Imperato A: Drugs abused by humans preferentially increase synaptic dopamine concentrations. Proc Natl Acad Sci USA 1988; 85:5274-5278
3. Imperato A, DiChiara G: Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats. J Pharmacol ExpTher 1986; 239:219-228
4. Benwell MEM, Balfour DJK: The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. BrJ Pharmacol 1992; 105:849-856
5. Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay J-M, Puech AJ: Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 1995; 38:756-761
6. Oreland L, Fowler CJ, Schalling D: Low platelet monoamine oxidase activity in cigarette smokers. Life Sci 1981; 29:2511-2518
7. Norman TR, Chamberlain KG, French MA: Platelet monoamine oxidase activity: low activity in cigarette smokers. Psychiatry Res 1987; 20:199-205
8. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP: Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996; 93:14065-14069
9. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R: Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379:733-736
10. Blake DD, Weathers FW, Nagy LN, Kaloupek DG, Klauminzer G, Charney DS, Keane TM: A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behavior Therapy 1990; 18:187-188
11. Geracioti TD, Orth DN, Ekhator NN, Blumenkopf B, Loosen PT: Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 1992; 74:1325-1330
12. Geracioti TD Jr, Keck PE Jr, Ekhator NN, West SA, Baker DG, Hill KK, Bruce AB, Wortman MD: Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid. Biol Psychiatry 1998; 44:228-233
13. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195-1202
14. Ascher JA, Cole JO, Colin J-N, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56:395-401
15. Kopin IJ, Bankiewicz KS, Harvey-White J: Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP. Neuropsychopharmacology 1988; 1:119-125
16. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM: Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995; 152:453-455
17. Ebinger G, Michotte Y, Herregodts P: The significance of homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations in human lumbar cerebrospinal fluid. J Neurochem 1987; 48:1725-1729
18. Tohgi H, Abe T, Yamazaki K, Saheki M, Takahashi S, Tsukamoto Y: Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995; 192:165-168